Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition

Nature Communications

Volumn 6, Issue , 2015, Pages

  Russell, Ronan ^a   Perkhofer, Lukas ^a   Liebau, Stefan ^b   Lin, Qiong ^c   Lechel, André ^a   Feld, Fenja M ^a   Hessmann, Elisabeth ^d   Gaedcke, Jochen ^d   Güthle, Melanie ^a   Zenke, Martin ^c   Hartmann, Daniel ^e   Von Figura, Guido ^f   Weissinger, Stephanie E ^a   Rudolph, Karl Lenhard ^g   Möller, Peter ^a   Lennerz, Jochen K ^a   Seufferlein, Thomas ^a   Wagner, Martin ^a   Kleger, Alexander ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g FRITZ LIPMANN INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BONE MORPHOGENETIC PROTEIN 4; TRANSFORMING GROWTH FACTOR BETA; ATM PROTEIN, HUMAN; ATM PROTEIN, MOUSE; KRAS2 PROTEIN, MOUSE; MESSENGER RNA; PROTEIN P21;

CANCER; COHORT ANALYSIS; GENE EXPRESSION; GENETIC ANALYSIS; HOMINID; LESION; MUTATION; RODENT;

ACINAR CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL DEDIFFERENTIATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ADULT; AGED; ANIMAL; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY; WESTERN BLOTTING;

MUS;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BLOTTING, WESTERN; BONE MORPHOGENETIC PROTEIN 4; CARCINOMA, PANCREATIC DUCTAL; CELL SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84938151107     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8677     Document Type: Article

References (70)

1. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA. Cancer J. Clin. 60, 277-300 (2010).
2. Wellner, U. et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 11, 1487-1495 (2009).
3. Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495-501 (2015).
4. Stathis, A. & Moore, M. J. Advanced pancreatic carcinoma: current treatment and future challenges. Nat. Rev. Clin.Oncol. 7, 163-172 (2010).
5. Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399-405 (2012).
6. Bakkenist, C. J. & Kastan, M. B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421, 499-506 (2003).
7. Matsuoka, S. et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-1166 (2007).
8. Mu, J. J. et al. A proteomic analysis of ataxia telangiectasia-mutated (ATM)/ATM-Rad3-related (ATR) substrates identifies the ubiquitin-proteasome system as a regulator for DNA damage checkpoints. J. Biol. Chem. 282, 17330-17334 (2007).
9. Shiloh, Y. & Ziv, Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat. Rev. Mol. Cell Biol. 14, 197-210 (2013).
10. Cremona, C. A. & Behrens, A. ATM signalling and cancer. Oncogene 33, 3351-3360 (2013).
11. FitzGerald, M. G. et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat. Genet. 15, 307-310 (1997).
12. Grant, R. C. et al. Exome sequencing identifies nonsegregating nonsense ATM and PALB2 variants in familial pancreatic cancer. Hum. Genomics 7, 11 (2013).
13. Roberts, N. J. et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Disc. 2, 41-46 (2012).
14. Grant, R. C. et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology 148, 556-564 (2015).
15. Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008).
16. Murphy, S. J. et al. Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. Gastroenterology 145, 1098-1109 e1091 (2013).
17. Kamphues, C. et al. Ataxia-telangiectasia-mutated protein kinase levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a strong indicator of poor survival. Pancreas 44, 296-301 (2015).
18. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450 (2003).
19. Kopp, J. L. et al. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 22, 737-750 (2012).
20. Lu, S. et al. Atm-haploinsufficiency enhances susceptibility to carcinogen-induced mammary tumors. Carcinogenesis 27, 848-855 (2006).
21. Bowen, T. J. et al. Atm heterozygosity cooperates with loss of Brca1 to increase the severity of mammary gland cancer and reduce ductal branching. Cancer Res. 65, 8736-8746 (2005).
22. Spring, K. et al. Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer. Nat. Genet. 32, 185-190 (2002).
23. Thompson, D. et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J. Natl Cancer Inst. 97, 813-822 (2005).
24. Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864-870 (2005).
25. Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349-361 (2012).
26. Feig, C. et al. The pancreas cancer microenvironment. Clin.Cancer Res. 18, 4266-4276 (2012).
27. Guo, W. et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148, 1015-1028 (2012).
28. Groger, C. J., Grubinger, M., Waldhor, T., Vierlinger, K. & Mikulits, W. Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression. PloS ONE 7, e51136 (2012).
29. Cheng, W. Y., Kandel, J. J., Yamashiro, D. J., Canoll, P. & Anastassiou, D. A multi-cancer mesenchymal transition gene expression signature is associated with prolonged time to recurrence in glioblastoma. PloS ONE 7, e34705 (2012).
30. Luche, H., Weber, O., Nageswara Rao, T., Blum, C. & Fehling, H. J. Faithful activation of an extra-bright red fluorescent protein in "knock-in" Cre-reporter mice ideally suited for lineage tracing studies. Eur. J. Immunol. 37, 43-53 (2007).
31. Reichert, M. et al. Isolation, culture and genetic manipulation of mouse pancreatic ductal cells. Nat. Protoc. 8, 1354-1365 (2013).
32. Polyak, K. & Weinberg, R. A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9, 265-273 (2009).
33. Van der Flier, L. G. et al. The intestinal Wnt/TCF signature. Gastroenterology 132, 628-632 (2007).
34. Merlos-Suárez, A. et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 5, 511-524 (2011).
35. Hermann, P. C. et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323 (2007).
36. Guzman-Ayala, M. et al. Graded Smad2/3 activation is converted directly into levels of target gene expression in embryonic stem cells. PloS ONE 4, e4268 (2009).
37. Duan, W. et al. Overexpression of Nodal induces a metastatic phenotype in pancreatic cancer cells via the Smad2/3 pathway. Oncotarget 6, 1490-1506 (2015).
38. Weidgang, C. E. et al. TBX3 directs cell-fate decision toward mesendoderm. Stem Cell Rep. 1, 248-265 (2013).
39. Fang, R. et al. Nodal promotes aggressive phenotype via Snail-mediated epithelial-mesenchymal transition in murine melanoma. Cancer Lett. 333, 66-75 (2013).
40. Gordon, K. J., Kirkbride, K. C., How, T. & Blobe, G. C. Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2. Carcinogenesis 30, 238-248 (2009).
41. Kishigami, S. & Mishina, Y. BMP signaling and early embryonic patterning. Cytokine Growth Factor Rev. 16, 265-278 (2005).
42. Deng, H., Ravikumar, T. S. & Yang, W. L. Overexpression of bone morphogenetic protein 4 enhances the invasiveness of Smad4-deficient human colorectal cancer cells. Cancer Lett. 281, 220-231 (2009).
43. Yu, P. B. et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat. Med. 14, 1363-1369 (2008).
44. Richter, A. et al. BMP4 promotes EMT and mesodermal commitment in human embryonic stem cells via SLUG and MSX2. Stem Cells 32, 636-648 (2014).
45. Hong, S. M. et al. Telomeres are shortened in acinar-to-ductal metaplasia lesions associated with pancreatic intraepithelial neoplasia but not in isolated acinar-to-ductal metaplasias. Modern Pathol. 24, 256-266 (2011).
46. Vege, S. S., Ziring, B., Jain, R., Moayyedi, P. & Clinical Guidelines, C. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology 148, 819-822 (2015).
47. Adsay, V. et al. Pathologic evaluation and reporting of intraductal papillary mucinous neoplasms of the pancreas and other tumoral intraepithelial neoplasms of pancreatobiliary tract: Recommendations of Verona Consensus Meeting. Ann. Surg. 00, 1-16 (2015).
48. Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500-503 (2011).
49. Cano, C. E. et al. Genetic inactivation of Nupr1 acts as a dominant suppressor event in a two-hit model of pancreatic carcinogenesis. Gut 63, 984-995 (2014).
50. Zhang, G. et al. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PloS ONE 7, e31507 (2012).
51. Faca, V. M. et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS. Med. 5, e123 (2008).
52. Yu, G. et al. Expression of ATM protein and its relationship with p53 in pancreatic carcinoma with tissue array. Pancreas 28, 421-426 (2004).
53. Fedier, A. et al. Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites. Ann. Oncol. 14, 938-945 (2003).
54. Squatrito, M. et al. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell 18, 619-629 (2010).
55. Jiang, H. et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 23, 1895-1909 (2009).
56. Kwong, L. N., Weiss, K. R., Haigis, K. M. & Dove, W. F. Atm is a negative regulator of intestinal neoplasia. Oncogene 27, 1013-1018 (2008).
57. Smirnov, D. A. & Cheung, V. G. ATM gene mutations result in both recessive and dominant expression phenotypes of genes and microRNAs. Am. J. Hum. Genet. 83, 243-253 (2008).
58. Kirshner, J. et al. Inhibition of transforming growth factor-beta1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. Cancer Res. 66, 10861-10869 (2006).
59. Wang, Y. et al. Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene 30, 1470-1480 (2011).
60. Lonardo, E., Frias-Aldeguer, J., Hermann, P. C. & Heeschen, C. Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness. Cell Cycle 11, 1282-1290 (2012).
61. Kong, B. et al. Increased expression of Nodal correlates with reduced patient survival in pancreatic cancer. Pancreatology 15, 156-161 (2015).
62. Levy, L. & Hill, C. S. Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol. Cell Biol. 25, 8108-8125 (2005).
63. Bernstein, J. L. et al. Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. Hum. Mutat. 21, 542-550 (2003).
64. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248 (2001).
65. Kawaguchi, Y. et al. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat. Genet. 32, 128-134 (2002).
66. Zha, S., Sekiguchi, J., Brush, J. W., Bassing, C. H. & Alt, F. W. Complementary functions of ATM and H2AX in development and suppression of genomic instability. Proc. Natl Acad. Sci. USA 105, 9302-9306 (2008).
67. Lobe, C. G. et al. Z/AP, a double reporter for cre-mediated recombination. Dev. Biol. 208, 281-292 (1999).
68. Hruban, R. H. et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am. J. Surg. Pathol. 28, 977-987 (2004).
69. Hamilton, S. R. & Aaltonen, L. R. Pathology and Genetics of Tumorous of the Digestive System (IARC Press, 2000).
70. Wagner, M. et al. Transgenic Overexpression of amphireguin induces a mitogenic response selectively in pancreatic duct cells. Gastroenterology 7, 1898-1912 (2002).